The spin-off Peptomyc and VHIO awarded €4 million from the Spanish Ministry of Science and Innovation to advance the clinical development of the first direct MYC inhibitor20 / 12 / 23|
Peptomyc announces first patient dosed in Phase Ib trial of OMO-103 in combination with standard of care chemotherapy in first-line metastatic PDAC patients28 / 11 / 23|
Peptomyc is awarded €5 million from the Horizon Europe EIC Accelerator Program to conduct a Phase 1b clinical trial with OMO-103 in patients and scale up its manufacturing process31 / 10 / 23|
Peptomyc announces the approval of its Phase 1b trial testing OMO-103 in combination with standard of care in PDAC patients27 / 07 / 23|
Results from phase I clinical trial of the first drug to successfully inhibit the MYC protein, which drives many common cancers01 / 11 / 22|
Omomyc as the first MYC-targeted therapy to successfully complete a phase I clinical trial28 / 10 / 22|
TODAY in El Mundo: “Así avanza el fármaco español pionero en su estrategia contra el cáncer”26 / 10 / 22|
TODAY in La Vanguardia: “Èxit del primer assaig en pacients del fàrmac Omomyc contra el càncer”26 / 10 / 22|
MYC inhibition halts metastatic breast cancer progression by blocking tumor growth, invasion & seeding21 / 02 / 22|
